These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12697901)

  • 1. Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation.
    Kopin AS; McBride EW; Chen C; Freidinger RM; Chen D; Zhao CM; Beinborn M
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5525-30. PubMed ID: 12697901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists.
    Bläker M; Ren Y; Gordon MC; Hsu JE; Beinborn M; Kopin AS
    Mol Pharmacol; 1998 Nov; 54(5):857-63. PubMed ID: 9804620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea]: an irreversible cholecystokinin type-B receptor antagonist.
    Dunlop J; Brammer N; Evans N; Ennis C
    Biochem Pharmacol; 1997 Jul; 54(1):81-5. PubMed ID: 9296353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial agonism, neutral antagonism, and inverse agonism at the human wild-type and constitutively active cholecystokinin-2 receptors.
    Foucaud M; Tikhonova IG; Langer I; Escrieut C; Dufresne M; Seva C; Maigret B; Fourmy D
    Mol Pharmacol; 2006 Mar; 69(3):680-90. PubMed ID: 16293711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy.
    Kopin AS; McBride EW; Gordon MC; Quinn SM; Beinborn M
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):11043-8. PubMed ID: 9380756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of 11C-labeled nonpeptide antagonists for cholecystokinin receptors: [11C]L-365,260 and [11C]L-365,346.
    Haradahira T; Inoue O; Kobayashi K; Suzuki K
    Nucl Med Biol; 1998 Apr; 25(3):203-8. PubMed ID: 9620624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.
    Beinborn M; Chen C; DeMeo L; McBride EW; Kopin AS
    Yale J Biol Med; 1998; 71(3-4):337-46. PubMed ID: 10461364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
    Castro JL; Ball RG; Broughton HB; Russell MG; Rathbone D; Watt AP; Baker R; Chapman KL; Fletcher AE; Patel S; Smith AJ; Marshall GR; Ryecroft W; Matassa VG
    J Med Chem; 1996 Feb; 39(4):842-9. PubMed ID: 8632408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonpeptide cholecystokinin-2 receptor agonists.
    Kalindjian SB; Dunstone DJ; Low CM; Pether MJ; Roberts SP; Tozer MJ; Watt GF; Shankley NP
    J Med Chem; 2001 Apr; 44(8):1125-33. PubMed ID: 11312913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCK receptor antagonists.
    Dunlop J
    Gen Pharmacol; 1998 Oct; 31(4):519-24. PubMed ID: 9792209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties.
    Beinborn M; Quinn SM; Kopin AS
    J Biol Chem; 1998 Jun; 273(23):14146-51. PubMed ID: 9603914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite modulation of apomorphine- or amphetamine-induced stereotypy by antagonists of CCK receptors.
    Tieppo CA; Ferreira FS; Sassatani AS; Felicio LF; Nasello AG
    Eur J Pharmacol; 2000 Jan; 387(2):189-96. PubMed ID: 10650159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419.
    Tabuchi S; Ito H; Sogabe H; Kuno M; Kinoshita T; Katumi I; Yamamoto N; Mitsui H; Satoh Y
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):1-15. PubMed ID: 10705468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors.
    Evans BE
    Z Gastroenterol Verh; 1991 Mar; 26():269-71. PubMed ID: 1714170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.